ICU Medical (NASDAQ:ICUI) Director Buys $151,704.00 in Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director David Greenberg purchased 1,200 shares of the business’s stock in a transaction on Wednesday, August 27th. The stock was purchased at an average price of $126.42 per share, with a total value of $151,704.00. Following the purchase, the director owned 7,960 shares of the company’s stock, valued at approximately $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

ICU Medical Stock Performance

Shares of ICUI stock opened at $127.66 on Friday. The stock has a market cap of $3.15 billion, a P/E ratio of -83.99 and a beta of 0.88. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. The company has a fifty day moving average price of $126.87 and a two-hundred day moving average price of $135.94. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $196.26.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating analysts’ consensus estimates of $1.44 by $0.66. The firm had revenue of $543.57 million during the quarter, compared to analysts’ expectations of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company’s revenue for the quarter was down 8.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.56 earnings per share. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. As a group, equities analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Piper Sandler assumed coverage on shares of ICU Medical in a research report on Friday, August 15th. They issued an “overweight” rating and a $145.00 price objective on the stock. Raymond James Financial dropped their price objective on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research report on Friday, August 8th. Finally, Wall Street Zen lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $179.00.

Institutional Investors Weigh In On ICU Medical

Large investors have recently bought and sold shares of the company. Quarry LP grew its stake in ICU Medical by 764.3% during the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 214 shares in the last quarter. Cullen Frost Bankers Inc. acquired a new stake in ICU Medical during the second quarter worth about $38,000. GAMMA Investing LLC grew its stake in ICU Medical by 27.2% during the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 153 shares in the last quarter. Blue Trust Inc. grew its stake in ICU Medical by 23.0% during the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier’s stock worth $111,000 after buying an additional 150 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its stake in ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.